Mesoblast corporate update

New york, dec. 14, 2020 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update.

MESO Ratings Summary

MESO Quant Ranking